Differences in Mortality Among Patients With Asthma and COPD Hospitalized With COVID-19
Liu Y, Rajeevan H, Simonov M, Lee S, Wilson F, Desir G, Vinetz J, Yan X, Wang Z, Clark B, Possick J, Price C, Lutchmansingh D, Ortega H, Zaeh S, Gomez J, Cohn L, Gautam S, Chupp G. Differences in Mortality Among Patients With Asthma and COPD Hospitalized With COVID-19. The Journal Of Allergy And Clinical Immunology In Practice 2023, 11: 3383-3390.e3. PMID: 37454926, PMCID: PMC10787810, DOI: 10.1016/j.jaip.2023.07.006.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseType 2 inflammationCOVID-19 severitySOFA scoreAirway diseaseNoneosinophilic asthmaSequential Organ Failure Assessment scoreOrgan Failure Assessment scoreSevere coronavirus disease 2019Higher SOFA scoreMedian SOFA scoreRetrospective cohort studyObstructive pulmonary diseaseOdds of mortalityLower SOFA scoresCells/μLCOVID-19 outcomesCoronavirus disease 2019Logistic regression analysisCOVID-19Clinical confoundersAsthma patientsCohort studyImmunological factorsClinical featuresDupilumab improves long‐term outcomes in patients with uncontrolled, moderate‐to‐severe GINA‐based type 2 asthma, irrespective of allergic status
Rabe K, Pavord I, Busse W, Chupp G, Izuhara K, Altincatal A, Gall R, Pandit‐Abid N, Deniz Y, Rowe P, Jacob‐Nara J, Radwan A. Dupilumab improves long‐term outcomes in patients with uncontrolled, moderate‐to‐severe GINA‐based type 2 asthma, irrespective of allergic status. Allergy 2023, 78: 2148-2156. PMID: 37073882, DOI: 10.1111/all.15747.Peer-Reviewed Original ResearchConceptsParent study baselineType 2 inflammationPre-bronchodilator FEVAsthma exacerbation rateType 2 asthmaAllergic asthmaExacerbation rateSevere asthma exacerbation ratesSevere type 2 asthmaAsthma Control Questionnaire scoreACQ-5 scoresReduced exacerbation ratesLong-term outcomesLong-term treatmentAllergic statusDupilumab efficacyGINA guidelinesQUEST studyWeek 96Asthma controlUncontrolled asthmaWeek 48Allergic phenotypeLung functionQuestionnaire scores